Accès ouvert
2021
article
OpenAlex
Nada Alnaggar
Die koronare Herzkrankheit ist die häufigste Todesursache in Industrienationen weltweit. In dieser Studie haben wir bei 152 Patienten mit symptomatischer koronarer Herzerkrankung (KHK) und 15 gesunden Probanden thrombozytäres oxLDL, CXCR4 sowie CXCR7 untersucht. In dieser Studie wurde die thrombozytäre oxLDL Oberflächenexpression bei …
2018
article
OpenAlex
Oliver Borst, Patrick Muenzer, Nada Alnaggar, Sascha Geue et autres
Aims: Very low dose (VLD) factor Xa (FXa) inhibition in combination with acetylsalicylic acid (ASA) and clopidogrel is associated with improved outcomes in patients with acute coronary syndrome (ACS) with a tolerable bleeding risk profile. To date there are no data documenting …
de, nl, us
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Oliver Borst, Patrick Münzer, Nada Alnaggar, Sascha Geue et autres
inhibitor (clopidogrel/ticagrelor), whereas the pure platelet-dependent (PL-chip) thrombus formation was not affected at all. Adjunctive rivaroxaban therapy was not associated with significant differences in platelet aggregation assessed by light-transmission aggregometry (LTA). Nevertheless, according to fluorescence-activated cell sorter analysis, VLD rivaroxaban treatment resulted …
de, nl, us, gb, it
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Tobias Geisler, Patrick Muenzer, Nada Alnaggar, Sascha Geue et autres
2017
article
OpenAlex
Madhumita Chatterjee, Dominik Rath, Jörg Schlotterbeck, Johannes Rheinlaender et autres
AIMS: Hyperlipidaemia enhances susceptibility to thrombosis, while platelet oxidixed LDL (oxLDL) binding in acute coronary syndrome (ACS) correlates with activation status. This study explores the platelet lipidome in symptomatic coronary artery disease (CAD) patients and the functional consequences of the chemokine CXCL12 …
de
(code pays fourni par la source)